Vivos Therapeutics (VVOS) Cash from Operations Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.61 Bn | 175.32 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.95 Bn | 126.07 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.22 Bn | 99.00 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.29 Bn | 66.84 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.30 Bn | 44.63 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.31 Bn | 27.19 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.03 Bn | 25.75 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 27.01 Bn | 26.43 Bn | - | - |
| 9 | Koninklijke Philips | 24.04 Bn | 20.91 Bn | 2.07 Bn | 122.43% |
| 10 | Vivos Therapeutics | 5.84 Mn | 3.73 Mn | 3.06 Mn | -57.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.89% |
| Dec 31, 2025 | -27.60% |
| Sep 30, 2025 | -1.18% |
| Jun 30, 2025 | -13.49% |
| Mar 31, 2025 | -51.03% |
| Dec 31, 2024 | -9.14% |
| Sep 30, 2024 | -48.25% |
| Jun 30, 2024 | -7.87% |
| Mar 31, 2024 | 28.91% |
| Dec 31, 2023 | 10.32% |
| Sep 30, 2023 | 52.07% |
| Jun 30, 2023 | 38.69% |
| Mar 31, 2023 | 41.81% |
| Dec 31, 2022 | 26.90% |
| Sep 30, 2022 | -45.58% |
| Jun 30, 2022 | -24.71% |
| Mar 31, 2022 | -57.52% |
| Dec 31, 2021 | -13.93% |
| Sep 30, 2021 | -495.01% |
| Jun 30, 2021 | -293.33% |